Literature DB >> 8405521

A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin.

S R Lindheim1, S C Presser, E C Ditkoff, M A Vijod, F Z Stanczyk, R A Lobo.   

Abstract

OBJECTIVE: To determine the effects of estrogen and of added progestin on carbohydrate tolerance in postmenopausal women.
DESIGN: An insulin tolerance test (ITT) was used to assess insulin resistance in healthy post-menopausal women and to determine the effects of oral estrogen with and without added progestin on insulin sensitivity.
SETTING: A menopause research clinic at a University Medical Center. PATIENTS: Fifteen healthy postmenopausal and nine premenopausal women were studied after having not received any hormone preparations for > or = 4 weeks.
INTERVENTIONS: All subjects received a baseline ITT and postmenopausal women were then randomized to receive either 0.625 mg conjugated equine estrogen, 0.625 mg conjugated equine estrogen/10 mg progestin, or 1.25 mg conjugated equine estrogen for 2 months at which time a second ITT was performed. In the former two groups the women were treated for an additional 4 months to assess the long-term effects of treatment and had a third ITT performed at the end of 6 months. MAIN OUTCOME MEASURES: Fasting serum insulin and glucose were measured and K(itt) values were obtained at each visit in each group.
RESULTS: Forty-four percent of nonobese healthy postmenopausal women were found to have insulin resistance. The three groups differed significantly in their K(itt) responses. Estrogen replacement improved insulin sensitivity (K(itt) increased by 25%). However, 1.25 mg of conjugated equine estrogen caused a 24.7% decrease in K(itt) values and progestins attenuated the beneficial effects of 0.625 mg conjugated equine estrogen from baseline values (K(itt) decreased by 17.0%). Two- and 6-month values did not differ.
CONCLUSIONS: Insulin resistance is prevalent in healthy postmenopausal women. A moderate dose of estrogen appears to increase insulin sensitivity but higher doses may attenuate this benefit and progestins may cause a decrease in insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405521     DOI: 10.1016/s0015-0282(16)56218-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  22 in total

1.  Intravenous estrogens increase insulin clearance and action in postmenopausal women.

Authors:  R E Van Pelt; W S Gozansky; R S Schwartz; W M Kohrt
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-04-08       Impact factor: 4.310

2.  Hormone replacement therapy, body mass index and asthma in perimenopausal women: a cross sectional survey.

Authors:  F Gómez Real; C Svanes; E H Björnsson; K A Franklin; K Franklin; D Gislason; T Gislason; A Gulsvik; C Janson; R Jögi; T Kiserud; D Norbäck; L Nyström; K Torén; T Wentzel-Larsen; E Omenaas
Journal:  Thorax       Date:  2005-10-21       Impact factor: 9.139

3.  Acute modulation of adipose tissue lipolysis by intravenous estrogens.

Authors:  Rachael E Van Pelt; Wendolyn S Gozansky; Robert C Hickner; Robert S Schwartz; Wendy M Kohrt
Journal:  Obesity (Silver Spring)       Date:  2006-12       Impact factor: 5.002

Review 4.  Clinical opinion: the biologic and pharmacologic principles for age-adjusted long-term estrogen therapy.

Authors:  Morris Notelovitz
Journal:  MedGenMed       Date:  2006-03-28

5.  17β-estradiol Induces MMP-9 and MMP-13 in TMJ Fibrochondrocytes via Estrogen Receptor α.

Authors:  N Ahmad; S Chen; W Wang; S Kapila
Journal:  J Dent Res       Date:  2018-04-05       Impact factor: 6.116

6.  [Correlation analysis of serum progesterone with clinical indicators and common traditional Chinese medicine syndrome types in male type 2 diabetic patients].

Authors:  Xin Yang; Yue Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

Review 7.  Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.

Authors:  Carlo Campagnoli; Françoise Clavel-Chapelon; Rudolf Kaaks; Clementina Peris; Franco Berrino
Journal:  J Steroid Biochem Mol Biol       Date:  2005-07       Impact factor: 4.292

8.  Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.

Authors:  K L Margolis; D E Bonds; R J Rodabough; L Tinker; L S Phillips; C Allen; T Bassford; G Burke; J Torrens; B V Howard
Journal:  Diabetologia       Date:  2004-07-14       Impact factor: 10.122

9.  Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women.

Authors:  L Soranna; F Cucinelli; C Perri; G Muzj; M Giuliani; P Villa; A Lanzone
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

10.  Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion.

Authors:  Michael J Toth; Brian C Cooper; Richard E Pratley; Andrea Mari; Dwight E Matthews; Peter R Casson
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-04-15       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.